Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 18, 2009

India-Based CRO SIRO ClinPharm Allies with Regulatory Consultancy Firm CamReg

  • India-based CRO SIRO Clinpharm formed a strategic alliance with Cambridge Regulatory Services, a full-service regulatory consultancy for the pharmaceutical industry. The companies claim their partnership will provide clients with a one -stop, cost-effective solution for accessing expertise in clinical trials and drug registration.

    “Our alliance with CambReg will go a long way in helping small- and mid-sized companies cut through the regulatory maze in Europe,” says Chetan Tamhankar, Ph.D., SIRO Clinpharm’s COO.

    Karen James, M.D., at Cambridge Regulatory Services, adds, “The partnership will provide European pharma companies with increased confidence in accessing cost-effective clinical trials solutions, hence introducing new clients to SIRO. In return, SIRO will have the benefit of offering regulatory expertise through CamReg.”



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »